Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Descending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
69945-0450-01 69945-0450 sodium iodide, i-131 Sodium Iodide I-131 5.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral Oct. 27, 2015 July 1, 2018 No Longer Used
69945-0450-02 69945-0450 sodium iodide, i-131 Sodium Iodide I-131 5.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral Oct. 27, 2015 July 1, 2018 No Longer Used
69945-0450-03 69945-0450 sodium iodide, i-131 Sodium Iodide I-131 5.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral Oct. 27, 2015 July 1, 2018 No Longer Used
69945-0450-04 69945-0450 sodium iodide, i-131 Sodium Iodide I-131 5.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral Oct. 27, 2015 July 1, 2018 No Longer Used
69945-0450-05 69945-0450 sodium iodide, i-131 Sodium Iodide I-131 5.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral Oct. 27, 2015 July 1, 2018 No Longer Used
69945-0450-07 69945-0450 sodium iodide, i-131 Sodium Iodide I-131 5.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral Oct. 27, 2015 July 1, 2018 No Longer Used
50742-0483-99 50742-0483 fluorouracil FLUOROURACIL 5.0 g/100mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
00703-3019-12 00703-3019 Fluorouracil Adrucil 5.0 g/100mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2003 Oct. 31, 2020 No Longer Used
00069-0294-10 00069-0294 filgrastim-aafi Nivestym 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous March 11, 2019 In Use
55513-0546-01 55513-0546 Filgrastim Neupogen 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous April 7, 1997 In Use
55513-0546-10 55513-0546 Filgrastim Neupogen 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous April 7, 1997 In Use
63459-0920-59 63459-0920 tbo-filgrastim GRANIX 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 7, 2018 In Use
70121-1571-07 70121-1571 Filgrastim RELEUKO 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
00069-0292-01 00069-0292 filgrastim-aafi Nivestym 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Sept. 24, 2018 In Use
00069-0292-10 00069-0292 filgrastim-aafi Nivestym 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Sept. 24, 2018 In Use
54868-3050-00 54868-3050 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous Aug. 14, 2006 In Use
55513-0209-01 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0209-10 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0209-91 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
63459-0912-01 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0912-11 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0912-12 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0912-15 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0912-17 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous March 2, 2015 In Use
63459-0912-18 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Jan. 7, 2015 In Use
63459-0912-36 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous March 2, 2015 In Use
70121-1570-07 70121-1570 Filgrastim RELEUKO 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1570-01 70121-1570 Filgrastim RELEUKO 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
61314-0312-01 61314-0312 filgrastim-sndz Zarxio 480.0 ug/.8mL, 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Sept. 3, 2015 Feb. 28, 2021 No Longer Used
61314-0312-10 61314-0312 filgrastim-sndz Zarxio 480.0 ug/.8mL, 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Sept. 3, 2015 Feb. 28, 2021 No Longer Used
82705-0010-01 82705-0010 Epcoritamab-bysp EPKINLY 48.0 mg/.8mL Immunotherapy Monoclonal Antibody CD20, CD3 Subcutaneous May 19, 2023 In Use
57277-0107-45 57277-0107 carboplatin Injection Carboplatin 450.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 29, 2016 In Use
50742-0447-45 50742-0447 Carboplatin Carboplatin 450.0 mg/45mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 1, 2023 No Longer Used
00069-2299-30 00069-2299 dacomitinib Vizimpro 45.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 4, 2018 In Use
76189-0534-30 76189-0534 Ponatinib Hydrochloride Iclusig 45.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 14, 2012 July 26, 2020 No Longer Used
76189-0534-90 76189-0534 Ponatinib Hydrochloride Iclusig 45.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 14, 2012 July 26, 2020 No Longer Used
63459-0395-02 63459-0395 Bendamustine Hydrochloride Treanda 45.0 mg/.5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 5, 2014 April 30, 2017 No Longer Used
62935-0461-50 62935-0461 Leuprolide acetate Eligard 45.0 mg/.375mL Hormonal Therapy GnRH Agonist Subcutaneous March 6, 2023 In Use
68727-0745-01 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
68727-0745-02 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
68727-0745-05 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
63539-0252-02 63539-0252 Elranatamab-bcmm Elrexfio 44.0 mg/1.1mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Aug. 15, 2023 In Use
00069-2522-02 00069-2522 Elranatamab-bcmm Elrexfio 44.0 mg/1.1mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Aug. 15, 2023 In Use
55513-0132-01 55513-0132 trastuzumab-anns Kanjinti 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous June 11, 2019 In Use
83257-0003-01 83257-0003 Trastuzumab-dkst OGIVRI 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 1, 2023 In Use
00069-0305-01 00069-0305 Trastuzumab-qyyp Trazimera 420.0 mg/20 mL Immunotherapy Monoclonal Antibody HER2 Intravenous Feb. 24, 2020 In Use
57962-0420-28 57962-0420 Ibrutinib IMBRUVICA 420.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0420-71 57962-0420 Ibrutinib IMBRUVICA 420.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 6, 2019 In Use
67457-0847-44 67457-0847 Trastuzumab OGIVRI 420.0 mg/ 20 mL Immunotherapy Monoclonal Antibody HER2 Intravenous Nov. 29, 2019 April 30, 2027 In Use
72851-0042-01 72851-0042 Leuprolide CAMCEVI 42.0 mg/mL Hormonal Therapy GnRH Agonist Subcutaneous Dec. 30, 2022 In Use
69448-0014-63 69448-0014 LEUPROLIDE CAMCEVI 42.0 mg/.37g Hormonal Therapy GnRH Agonist Subcutaneous April 5, 2022 In Use
54868-5802-00 54868-5802 Erythropoietin Procrit 40000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 13, 2007 In Use
59676-0340-00 59676-0340 Erythropoietin Procrit 40000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0340-01 59676-0340 Erythropoietin Procrit 40000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
00069-1309-04 00069-1309 epoetin alfa-epbx RETACRIT 40000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1309-10 00069-1309 epoetin alfa-epbx RETACRIT 40000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
59676-0304-00 59676-0304 Erythropoietin Procrit 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0304-01 59676-0304 Erythropoietin Procrit 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0304-02 59676-0304 Erythropoietin Procrit 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 Jan. 8, 2014 In Use
55513-0148-01 55513-0148 Epoetin alfa Epogen 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0148-10 55513-0148 Epoetin alfa Epogen 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
00069-1307-10 00069-1307 epoetin alfa-epbx RETACRIT 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
59353-0004-10 59353-0004 Epoetin alfa-epbx RETACRIT 4000.0 [iU]/mL, 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
54868-3348-01 54868-3348 Medroxyprogesterone Acetate Depo-Provera 400.0 mg/mL Hormonal Therapy Progestin Intramuscular Jan. 13, 1995 In Use
00009-0626-01 00009-0626 Medroxyprogesterone Acetate Depo-Provera 400.0 mg/mL Hormonal Therapy Progestin Intramuscular Nov. 1, 1960 In Use
55513-0956-01 55513-0956 Panitumumab Vectibix 400.0 mg/20mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct. 10, 2006 In Use
00069-0342-01 00069-0342 Bevacizumab-bvzr Zirabev 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan. 13, 2020 In Use
72606-0012-01 72606-0012 Bevacizumab-adcd Vegzelma 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous April 3, 2023 In Use
72606-0012-10 72606-0012 Bevacizumab-adcd Vegzelma 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous April 3, 2023 In Use
70121-1755-01 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-1755-07 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
50242-0061-01 50242-0061 Bevacizumab Avastin 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Feb. 26, 2004 In Use
50242-0061-10 50242-0061 Bevacizumab Avastin 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous April 1, 2019 Feb. 28, 2023 In Use
55513-0207-01 55513-0207 Bevacizumab-awwb MVASI 400.0 mg/16mL, 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous June 1, 2018 In Use
16714-0150-01 16714-0150 Triamcinolone Acetonide Triamcinolone Acetonide 400.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular Nov. 19, 2019 In Use
70121-1653-01 70121-1653 Triamcinolone Acetonide Triamcinolone Acetonide 400.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Dec. 11, 2017 In Use
70121-1655-01 70121-1655 Triamcinolone Acetonide Triamcinolone Acetonide 400.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Dec. 11, 2017 In Use
70121-1169-01 70121-1169 Triamcinolone Acetonide Triamcinolone Acetonide 400.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Dec. 11, 2017 In Use
67457-0623-10 67457-0623 TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE 400.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular May 8, 2023 In Use
00003-4522-11 00003-4522 Elotuzumab Empliciti 400.0 mg/1 Immunotherapy Monoclonal Antibody SLAMF7 Intravenous Nov. 30, 2015 In Use
00093-7630-56 00093-7630 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 4, 2016 In Use
60429-0926-30 60429-0926 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 30, 2016 In Use
60505-2901-00 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-01 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-03 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-05 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-09 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
43598-0345-05 43598-0345 Imatinib Imatinib 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 13, 2018 In Use
43598-0345-30 43598-0345 Imatinib Imatinib 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 13, 2018 In Use
43598-0345-31 43598-0345 Imatinib Imatinib 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 15, 2020 In Use
43598-0345-90 43598-0345 Imatinib Imatinib 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 13, 2018 In Use
47335-0475-13 47335-0475 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2016 In Use
47335-0475-64 47335-0475 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2016 In Use
47335-0475-83 47335-0475 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2016 In Use
47335-0475-88 47335-0475 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2016 In Use
59651-0241-03 59651-0241 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral July 23, 2020 In Use
59651-0241-30 59651-0241 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral July 23, 2020 In Use
59923-0724-30 59923-0724 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 1, 2020 In Use
65162-0795-03 65162-0795 Imatinib Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 8, 2019 In Use
65162-0795-09 65162-0795 Imatinib Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 8, 2019 In Use

Found 10,000 results in 9 milliseconds — Export these results